Long title
An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplasic syndrome patient (DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2).
Date receipt dossier
EU record number
CYAD-N2T-005
EudraCT number
2018-000205-22
Company / Sponsor
Celyad
Phase
I/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Different metastatic tumor type
Therapeutic approach
Immunotherapy
Genetic modification
NKG2D-chimeric antigen receptor
Method of transfer of nucleic acid of interest
Moloney Murine Leukemia Virus
Administered biological material
Autologous T cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor
Route of administration
Intravenous
Locations in Belgium
AZ Sint-Jan Brugge-Oostende AV, UZ Antwerpen, Institut Jules Bordet
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
NKR-2